Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer.
Interest in precision diagnostics has been fuelled by the concept that early detection of cancer would benefit patients; that is, if detected early, more tumours should be resectable and treatment more efficacious. Serum contains massive amounts of potentially diagnostic information, and affinity proteomics has risen as an accurate approach to decipher this, to generate actionable information that should result in more precise and evidence-based options to manage cancer. To achieve this, we need to move from single to multiplex biomarkers, a so-called signature, that can provide significantly increased diagnostic accuracy. This Opinion article focuses on the progress being made in identifying protein biomarker signatures of clinical utility, using blood-based proteomics.
Department of Immunotechnology, CREATE Health Translational Cancer Center, Medicon Village (Bldg 406), Lund University, 223 81 Lund, Sweden.
Carl A K
CA
Borrebaeck
D014408:Biomarkers, Tumor / Q000097:blood*; D019295:Computational Biology; D055088:Early Detection of Cancer; D023281:Genomics; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis* / Q000628:therapy; D040901:Proteomics
D014408:Biomarkers, Tumor